ÂÜÀòÂÒÂ×

Inna Thalmann, PhD, currently serves as a Postdoctoral Fellow at the University of Oxford, focusing on the development of innovative algorithms for patient follow-up in clinical trials. As a Co-Founder and COO of Neurolytic Healthcare Inc., which was acquired in April 2023, Thalmann has been influential in securing backing from prominent investors such as Initialized Capital, Y Combinator, and Illumina, while also being a member of Y Combinator's S21 batch and the Illumina Accelerator Cambridge. Thalmann completed a PhD in Health Economics at the University of Oxford and has extensive experience in public policy and health economics, including roles at LSE Department of Health Policy and Deloitte Belgium, complemented by a strong educational background with degrees from The American University of Paris and LSE.